Severity of hearing loss after platinum chemotherapy in childhood cancer survivors

Sven Strebel, Luzius Mader, Tomáš Sláma, Nicolas Waespe, Annette Weiss, Ross Parfitt, Antoinette Am Zehnhoff-Dinnesen, Martin Kompis, Nicolas X von der Weid, Marc Ansari, Claudia E Kuehni, Sven Strebel, Luzius Mader, Tomáš Sláma, Nicolas Waespe, Annette Weiss, Ross Parfitt, Antoinette Am Zehnhoff-Dinnesen, Martin Kompis, Nicolas X von der Weid, Marc Ansari, Claudia E Kuehni

Abstract

Background: Hearing loss is a potential side effect from childhood cancer treatment. We described the severity of hearing loss assessed by audiometry in a representative national cohort of childhood cancer survivors (CCS) and identified clinical risk factors.

Procedure: We included all CCS from the Swiss Childhood Cancer Registry who were diagnosed ≤18 age and treated with platinum-based chemotherapy between 1990 and 2014. We extracted audiograms, treatment-related information, and demographic data from medical records. Two reviewers independently assessed the severity of hearing loss at latest follow-up using the Münster Ototoxicity Scale. We used ordered logistic regression to identify clinical risk factors for severity of hearing loss.

Results: We analyzed data from 270 CCS. Median time from cancer diagnosis to last audiogram was 5 years (interquartile range 2.5-8.1 years). We found 53 (20%) CCS with mild, 78 (29%) with moderate, and 75 (28%) with severe hearing loss. Higher severity grades were associated with (a) younger age at cancer diagnosis (odds ratio [OR] 5.4, 95% confidence interval [CI]: 2.5-12.0 for <5 years); (b) treatment in earlier years (OR 4.8, 95% CI: 2.1-11.0 for 1990-1995); (c) higher cumulative cisplatin doses (OR 13.5, 95% CI: 4.7-38.8 for >450 mg/m2 ); (d) concomitant cranial radiation therapy (CRT) (OR 4.4, 95% CI: 2.5-7.8); and (e) hematopoietic stem cell transplantation (HSCT) (OR 2.7, 95% CI: 1.0-7.2).

Conclusion: Three of four CCS treated with platinum-based chemotherapy experienced some degree of hearing loss. We recommend closely monitoring patient's hearing function if treated at a young age with high cumulative cisplatin doses, and concomitant CRT as part of long-term care.

Keywords: cancer registry; childhood cancer survivors; cranial radiation; ototoxicity; platinum compounds.

© 2022 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.

References

REFERENCES

    1. Landier W. Ototoxicity and cancer therapy. Cancer. 2016;122(11): 1647-1658.
    1. Weiss A, Sommer G, Kasteler R, et al. Long-term auditory complications after childhood cancer: a report from the Swiss Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2017;64(2):364-373.
    1. Langer T, Am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O. Understanding platinum-induced ototoxicity. Trends Pharmacol Sci. 2013;34(8):458-469.
    1. Clemens E, vanden Heuvel-Eibrink MM, Mulder RL, et al. Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. Lancet Oncol. 2019;20(1):e29-e41.
    1. Bass JK, Liu W, Banerjee P, et al. Association of hearing impairment with neurocognition in survivors of childhood cancer. JAMA Oncol. 2020;6(9):1363-1371.
    1. Weiss A, Sommer G, Schindera C, et al. Hearing loss and quality of life in survivors of paediatric CNS tumours and other cancers. Qual Life Res. 2019;28(2):515-521.
    1. Orgel E, O'Neil SH, Kayser K, et al. Effect of sensorineural hearing loss on neurocognitive functioning in pediatric brain tumor survivors. Pediatr Blood Cancer. 2016;63(3):527-534.
    1. Clemens E, deVries AC, Pluijm SF, et al. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: a DCOG late-effects study. Eur J Cancer. 2016;69:77-85.
    1. Cohen-Cutler S, Wong K, Mena V, et al. Hearing loss risk in pediatric patients treated with cranial irradiation and cisplatin-based chemotherapy. Int J Radiat Oncol Biol Phys. 2021;110(5):1488-1495.
    1. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005;23(34):8588-8596.
    1. Qaddoumi I, Bass JK, Wu J, et al. Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol. 2012;30(10):1034-1041.
    1. Kolinsky DC, Hayashi SS, Karzon R, Mao J, Hayashi RJ. Late onset hearing loss: a significant complication of cancer survivors treated with cisplatin containing chemotherapy regimens. J Pediatr Hematol Oncol. 2010;32(2):119-123.
    1. Camet ML, Spence A, Hayashi SS, et al. Cisplatin ototoxicity: examination of the impact of dosing, infusion times, and schedules in pediatric cancer patients. Front Oncol. 2021;11:673080.
    1. Warrier R, Chauhan A, Davluri M, Tedesco SL, Nadell J, Craver R. Cisplatin and cranial irradiation-related hearing loss in children. Ochsner J. 2012;12(3):191-196.
    1. Lewis MJ, DuBois SG, Fligor B, Li X, Goorin A, Grier HE. Ototoxicity in children treated for osteosarcoma. Pediatr Blood Cancer. 2009;52(3):387-391.
    1. Brinkman TM, Bass JK, Li Z, et al. Treatment-induced hearing loss and adult social outcomes in survivors of childhood CNS and non-CNS solid tumors: results from the St. Jude Lifetime Cohort Study. Cancer. 2015;121(22):4053-4061.
    1. Stöhr W, Langer T, Kremers A, et al. Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system. Cancer Invest. 2005;23(3):201-207.
    1. Moke DJ, Luo C, Millstein J, et al. Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study. Lancet Child Adolesc Health. 2021;5(4):274-283.
    1. Landier W, Knight K, Wong FL, et al. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales-a report from the Children's Oncology Group. J Clin Oncol. 2014;32(6):527-534.
    1. Nitz A, Kontopantelis E, Bielack S, et al. Prospective evaluation of cisplatin- and carboplatin-mediated ototoxicity in paediatric and adult soft tissue and osteosarcoma patients. Oncol Lett. 2013;5(1):311-315.
    1. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer. 2004;40(16):2445-2451.
    1. Peleva E, Emami N, Alzahrani M, et al. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec. Pediatr Blood Cancer. 2014;61(11):2012-2017.
    1. Bass JK, Huang J, Onar-Thomas A, et al. Concordance between the Chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. Pediatr Blood Cancer. 2014;61(4):601-605.
    1. Michel G, vonder Weid NX, Zwahlen M, Redmond S, Strippoli MP, Kuehni CE. Incidence of childhood cancer in Switzerland: the Swiss Childhood Cancer Registry. Pediatr Blood Cancer. 2008;50(1):46-51.
    1. Eidgenössischer Datenschutz- und Öffentlichkeitsbeauftragter (EDÖB). Leitfaden für die Bearbeitung von Personendaten im medizinischen Bereich. 2002. Accessed December 1, 2021.
    1. Kuehni CE, Rueegg CS, Michel G, et al. Cohort profile: the Swiss Childhood Cancer Survivor Study. Int J Epidemiol. 2012;41(6):1553-1564.
    1. Byrne J, Grabow D, Campbell H, et al. PanCareLIFE: the scientific basis for a European project to improve long-term care regarding fertility, ototoxicity and health-related quality of life after cancer occurring among children and adolescents. Eur J Cancer. 2018;103:227-237.
    1. Weiss A, Kuonen R, Brockmeier H, et al. Audiological monitoring in Swiss childhood cancer patients. Pediatr Blood Cancer. 2018;65(3):e26877.
    1. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, third edition. Cancer. 2005;103(7):1457-1467.
    1. Schmidt CM, Bartholomäus E, Deuster D, Heinecke A, Dinnesen AG. [The “Muenster classification” of high frequency hearing loss following cisplatin chemotherapy]. HNO. 2007;55(4):299-306.
    1. Stevens G, Flaxman S, Brunskill E, Mascarenhas M, Mathers CD, Finucane M. Global and regional hearing impairment prevalence: an analysis of 42 studies in 29 countries. Eur J Public Health. 2013;23(1):146-152.
    1. Brock PR, Knight KR, Freyer DR, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston Ototoxicity Scale. J Clin Oncol. 2012;30(19):2408-2417.
    1. Clemens E, Brooks B, deVries ACH, vanGrotel M, vanden Heuvel-Eibrink MM, Carleton B. A comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAEv4.03 ototoxicity grading scales applied to 3,799 audiograms of childhood cancer patients treated with platinum-based chemotherapy. PLoS One. 2019;14(2):e0210646.
    1. Knight KR, Chen L, Freyer D, et al. Group-wide, prospective study of ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): a report from the Children's Oncology Group. J Clin Oncol. 2017;35(4):440-445.
    1. Langer T, Clemens E, Broer L, et al. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: results of the European PanCareLIFE cohort study. Eur J Cancer. 2020;138:212-224.
    1. Gertson K, Hayashi SS, Trinkaus K, Wan F, Hayashi RJ. Prevalence of ototoxicity following hematopoietic stem cell transplantation in pediatric patients. Biol Blood Marrow Transplant. 2020;26(1):107-113.
    1. Brock PR, Maibach R, Childs M, et al. Sodium thiosulfate for protection from cisplatin-induced hearing loss. N Engl J Med. 2018;378(25):2376-2385.
    1. Strebel S, Waespe N, Kuehni CE. Hearing loss in childhood cancer survivors. Lancet Child Adolesc Health. 2021;5(5):e17.
    1. vanAs JW, vanden Berg H, vanDalen EC. Platinum-induced hearing loss after treatment for childhood cancer. Cochrane Database Syst Rev. 2016;2016(8):Cd010181.
    1. Lafay-Cousin L, Purdy E, Huang A, et al. Early cisplatin induced ototoxicity profile may predict the need for hearing support in children with medulloblastoma. Pediatr Blood Cancer. 2013;60(2):287-292.
    1. Wells EM, Ullrich NJ, Seidel K, et al. Longitudinal assessment of late-onset neurologic conditions in survivors of childhood central nervous system tumors: a Childhood Cancer Survivor Study report. Neuro Oncol. 2018;20(1):132-142.
    1. Meijer AJM, Li KH, Brooks B, et al. The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments. Cancer. 2022;128(1):169-179.
    1. Guillaume DJ, Knight K, Marquez C, Kraemer DF, Bardo DM, Neuwelt EA. Cerebrospinal fluid shunting and hearing loss in patients treated for medulloblastoma. J Neurosurg Pediatr. 2012;9(4):421-427.
    1. Whittle SB, Williamson KC, Russell HV. Incidence and risk factors of bacterial and fungal infection during induction chemotherapy for high-risk neuroblastoma. Pediatr Hematol Oncol. 2017;34(5):331-342.
    1. Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Pediatr Blood Cancer. 2012;59(1):144-148.
    1. Moeller BJ, Chintagumpala M, Philip JJ, et al. Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy. Radiat Oncol. 2011;6:58.
    1. Whelan K, Stratton K, Kawashima T, et al. Auditory complications in childhood cancer survivors: a report from the childhood cancer survivor study. Pediatr Blood Cancer. 2011;57(1):126-134.
    1. Paulino AC, Lobo M, Teh BS, et al. Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma. Int J Radiat Oncol Biol Phys. 2010;78(5):1445-1450.
    1. Beyea JA, Lau C, Cooke B, Hall S, Nathan PC, Gupta S. Long-term incidence and predictors of significant hearing loss requiring hearing assistive devices among childhood cancer survivors: a population-based study. J Clin Oncol. 2020;38(23):2639-2646.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel